San Diego-centered Viking Therapeutics marked itself as a significant competitor from the weight loss drug marketplace in February soon after revealing promising facts from a mid-stage trial of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when presented being a weekly injection As well as in March t